Search

Your search keyword '"Ong, Elodie"' showing total 43 results
Start Over Author "Ong, Elodie" Language english
43 results on '"Ong, Elodie"'

2. Successful Thrombectomy Improves Functional Outcome in Tandem Occlusions with a Large Ischemic Core

Author

Lapergue, Bertrand, Wang, Adrien, Consoli, Arturo, Coskun, Oguzhan, Maria, Federico Di, Pizzuto, Silvia, Sgreccia, Alessandro, Benoit, Charline, Gorza, Lucas, Weisenburger-Lile, David, Jabeur, Waliyde, Maia, Tchikviladze, Evrard, Serge, Rodesch, Georges, Blanc, Raphaël, Obadia, Michael, Desilles, Jean-Philippe, Piotin, Michel, Seners, Pierre, Smajda, Stanislas, Escalard, Simon, Maier, Benjamin, Sabben, Candice, Redjem, Hocine, Mikaelmazhigi, Adwan, Grace, Delvoye, François, Raaisi, Amira Al, Boisseau, William, Eker, Omer, Cho, Tae-Hee, Derex, Laurent, Fontaine, Julia, Mechtouff, Laura, Nighoghossian, Norbert, Ong, Elodie, Rascle, Lucie, Riva, Roberto, Turjman, Françis, Laubacher, Morgane, Beyragued, Mehdi, Berthezene, Yves, Hermier, Marc, Roxanna, Ameli, Bani-Sadr, Alexandre, Filip, Andrea, Cappucci, Matteo, Bourcier, Romain, Duport, Benjamin Daumas, Alexandre, Pierre Louis, Lenoble, Cédric, Hubertdesal, Gaalon, Solène De, Guillon, Benoît, Preterre, Cécile, Tessier, Guillaume, Lionnet, Arthur, Gory, Benjamin, Humbertjean-Selton, Lisa, Anxionnat, René, Derelle, Anne-Laure, Liao, Liang, Schmitt, Emmanuelle, Planel, Sophie, Richard, Sébastien, Mione, Gioia, Lacour, Jean-Christophe, Douarinou, Marian, Micard, Emilien, Chen, Bailiang, Audibert, Gérard, Masson, Agnès, Alb, Lionel, Beaumont, Marine, Tabarna, Adriana, Voicu, Marcela, Barthel, Grégoire, Podar, Iona, Brezeanu, Madalina, Reitter, Marie, Zhu, François, Marnat, Gaultier, Liegey, Jean-Sébastien, Briau, Pierre, Papillon, Lisa, Sibon, Igor, Barreau, Xavier, Papaxanthos, Jean, Berge, Jérome, Debruxelles, Sabrina, Olindo, Stephane, Poli, Mathilde, Renou, Pauline, Sagnier, Sharmila, Tourdias, Thomas, Courret, Thomas, Lucas, Ludovic, Milnerowicz, Malgorzata, Dargazanli, Cyril, Costalat, Vincent, Mourand, Isabelle, Arquizan, Caroline, Corti, Lucas, Adrien, Schiphorst, Ter, Federico, Cagnazzo, Derraz, Imad, Mahmoudi, Mehdi, Lefevre, Pierre-Henri, Gascou, Grégory, Spelle, Laurent, Caroff, Jildaz, Denier, Christian, Chalumeau, Vanessa, Mihalea, Cristian, Nicolaslegris, Ozanne, Augustin, Ikka, Leon, Chassin, Olivier, Gallas, Sophie, Venditti, Laura, Marianasarov, Cortese, Jonathan, Ferre, Jean-Christophe, Vannier, Stephane, Ronziere, Thomas, Veronica Lassalle, Maria, Gauvrit, Jean-Yves, Tracol, Clément, Boustia, Abdelghani Fakhreddine, Malrain, Cécile, Beaufreton, Edouard, Lapotre, Thibault, Alias, Quentin, Hissier, Julien, Guillen, Maud, Eugene, François, Chivot, Cyril, Courselle, Audrey, Ouin, Elisa, Lamy, Chantal, Delaforge, Kevin, Fernandez, Manuel, Vial, Jérémie, Laferte, Quentin, Desdoit, Xavier, Timsit, Serge, Jourdain, Aurore, Gentric, Jean-Christophe, Ognard, Julien, Viakhireva, Irina, Coris, Jordan, Prud'hon, Sabine, Merrien, François-Mathias, Marechal, Denis, Bruguet, Marie, Rousseau, Pierre Yves, Goas, Philippe, Boulanger, Marion, Touze, Emmanuel, Vivien, Denis, Barbier, Charlotte, Schneckenburger, Romain, Salaris, Fabrizio, Cogez, Julien, Guettier, Sophie, Porte, Estelle La, Bouchart, Jean, Mounayer, Charbel, Rouchaud, Aymeric, Saleme, Suzana, Forestier, Géraud, Clarencon, Frédéric, Rosso, Charlotte, Leder, Sara, Baronnet, Flore, Crozier, Sophie, Leger, Anne, Premat, Kevin, Eimad, Shotar, Lenck, Stéphanie, Sourour, Nader, Bottin, Laure, Ghazanfari, Sam, Yger, Marion, Alamowitch, Sonia, Delorme, Stephen, Wittwer, Aymeric, Vassilev, Christine, Naggara, Olivier, Turc, Guillaume, Hassen, Wagih Ben, Kerleroux, Basile, Trystram, Denis, Rodriguez-Regent, Christine, Ozkul-Wermester, Ozlem, Papagiannaki, Chrysanthi, Massardier, Evelyne, Triquenot, Aude, Lefebvre, Margaux, Burel, Julien, Viguier, Alain, Cognard, Christophe, Januel, Anne Christine, Albucher, Jean-François, Calviere, Lionel, Olivot, Jean-Marc, Darcourt, Jean, Raposo, Nicolas, Bonneville, Fabrice, Bellanger, Guillaume, Fontaine, Louis, Tall, Philippe, Thalamas, Claire, Geerearts, Thomas, Grepon, Antoine Faurie, Bourdain, Frédéric, Bernady, Patricia, Ballan, Guillaume, Bannier, Stéphanie, Ellie, Emmanuel, Flabeau, Olivier, Potenza, Julia, Soulages, Antoine, Lagoarde-Segot, Laurent, Cailliez, Hélène, Veunac, Louis, Higue, David, Lebras, Anthony, Adam, Sarah, Pegat, Benoit, Guen, Arnaud Le, Chedeville, François, Jouan, Jérémy, Demasles, Stéphanie, Richter, Johann Sebastian, Thierry Barroso, Bruno, Dahan, Camille, Gonnet, Alexis, Hubrecht, Régis, Lepine, Zoé, Castagnet, Hélène, Marasescu, Raluca, Heck, Olivier, Cuisenier, Pauline, Detante, Olivier, Wiki, Isabelle Favre, Bonaz, Clémentine, Garambois, Katia, Legris, Loic, Kastler, Adrian, Boubagra, Kamel, Berthet, Corentin, Charara, Stéphane, Wolff, Valérie, Pop, Raoul, Quenardelle, Véronique, Lauer, Valérie, Pierre-Paul, Irène, Roxanagheoca, Trzeciak, Malwina, Moulin, Solène, Tuan, Hua Vi, Pagano, Paolo, Doucet, Alexandre, Gelmini, Christophe, Manceau, Pierrefrançois, Paiusan, Laurentiu, Serre, Isabelle, Soize, Sébastien, Phuong Nguyen, Thi Ngoc, Sahnoun, Maher, Caucheteux, Nathalie, Ferrier, Anna, Zerroug, Abderrahim, Moreno, Ricardo, Chabert, Emmanuel, Lteif, Elie, Paulineparis, Bourgois, Nathalie, Raquin, Marie, Pasco-Papon, Anne, Girot, Jean Baptiste, Lecluse, Alderic, Godard, Sophie, L'allinec, Vincent, Janot, Kevin, Bibi, Richard, Gaudron, Marie, Bretonniere, Arnaud, Annan, Mariam, Ifergan, Héloïse, Boulouis, Grégoire, Pasi, Marco, Debiais, Séverine, Molinier, Elisabeth, Wietrich, Anthony, Ruche, Valérie, Lavandier, Karine, Bejot, Yannick, Lemogne, Brivale, Ricolfi, Fédéric, Baptiste, Laura, Thouant, Pierre, Duloquin, Gaulthier, Olivier Comby, Pierre, Charbonnier, Guillaume, Bonnet, Louise, Raybaud, Nicolas, Bouamra, Benjamin, Moulin, Thierry, Biondi, Alessandra, Finitsis, Stephanos, and Mazighi, Mikael

Published
2023
Full Text
View/download PDF

3. Safety and efficacy of prophylactic levetiracetam for prevention of epileptic seizures in the acute phase of intracerebral haemorrhage (PEACH): a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Peter-Derex, Laure, Philippeau, Frédéric, Garnier, Pierre, André-Obadia, Nathalie, Boulogne, Sébastien, Catenoix, Hélène, Convers, Philippe, Mazzola, Laure, Gouttard, Michel, Esteban, Maud, Fontaine, Julia, Mechtouff, Laura, Ong, Elodie, Cho, Tae-Hee, Nighoghossian, Norbert, Perreton, Nathalie, Termoz, Anne, Haesebaert, Julie, Schott, Anne-Marie, Rabilloud, Muriel, Pivot, Christine, Dhelens, Carole, Filip, Andrea, Berthezène, Yves, Rheims, Sylvain, Boutitie, Florent, and Derex, Laurent

Published
2022
Full Text
View/download PDF

4. More Than 50 Percent Reduction in LDL Cholesterol in Patients With Target LDL <70 mg/dL After a Stroke

Author

Amarenco, Pierre, Lavallée, Philippa C., Kim, Jong S., Labreuche, Julien, Charles, Hugo, Giroud, Maurice, Lee, Byung-Chul, Mahagne, Marie-Hélène, Meseguer, Elena, Nighoghossian, Norbert, Steg, Philippe Gabriel, Vicaut, Éric, Bruckert, Eric, Kim, Jong S, Touboul, Pierre-Jean, Leys, Didier, Béjot, Yannick, Pico, Fernando, Touzé, Emmanuel, Ducrocq, Gregory, Abtan, Jérémy, Varenne, Olivier, Touboul, Pierre-Jean, Kemmel, Agnes, Syana, Fausta, Ledra, Manele, Nagasara, Tharani, Ledjeroud, Mervette, Samia, Bahous, Hadia, Hafirassou, Hazare, Benyoub, Jaghouni, Ikrame El, Yelles, Nessima, Zemouri, Sofia, Ladjeroud, Mervette, Kerai, Salim, In, YunJeong, Hobeanu, Cristina, Guidoux, Celine, Cabrejo, Lucie, Lapergue, Bertrand, Sabben, Candice, Gonzalez-Valcarcel, Jaime, Rigual, Ricardo, Sirimarco, Gaia, Martin-Bechet, Anna, Viedma, Elena, Avram, Ioan, Samson, Yves, Rosso, Charlotte, Crozier, Sophie, Leder, Sara, Léger, Anne, Deltour, Sandrine, Mutlu, Gurkan, Yger, Marion, Zavanone, Chiara, Baronnet, Flore, Pires, Christine, Lapergue, Bertrand, Wang, Adrien, Evrard, Serge, Tchikviladze, Maya, Bourdain, Frédéric, Lopez, Delphine, Pico, Fernando, de la Tour, Laetitia Bayon, Chadenat, Marie-Laure, Duong, Duc Long, Genty, Solène, Hirel, Catherine, Mutlu, Gurkan, Nifle, Chantal, Servan, Jérôme, Stanciu, Daniela, Sudacevschi, Veronica, Tir, Mélissa, Troussière, Anne-Cécile, Yeung, Jennifer, Zeghoudi, Anne-Céline, Tidafi-Bayou, Ikram, Lachaud, Sylvain, Cho, Tae-Hee, Mechtouff, Laura, Ritzenthaller, Thomas, Derex, Laurent, Albanesi, Carlo, Ong, Elodie, Benoit, Amandine, Berhoune, Nadia, Felix, Sandra, Esteban-Mader, Maud, Sibon, Igor, Kazadi, Annabelle, Rouanet, François, Renou, Pauline, Debruxelles, Sabrina, Poli, Mathilde, Sagnier, Sharmila, Mas, Jean-Louis, Domigo, Valérie, Lamy, Catherine, Bodiguel, Eric, Grimaud, Jérôme, Bohotin, Valentin, Obadia, Michael, Sabben, Candice, Morvan, Erwan, Rodier, Gilles, Vadot, Wilfried, Hénon, Hilde, Cordonnier, Charlotte, Dumont, Frédéric, Bodenant, Marie, Lucas, Christian, Moulin, Solène, Dequatre, Nelly, Alamowitch, Sonia, Muresan, Jean-Paul, Drouet, Thomas, Gallea, Magalie, Dalloz, Marie-Amélie, Delorme, Stephen, Yger, Marion, Béjot, Yannick, Loisel, Philippe, Bonnin, Carine, Bernigal, Virginie, Osseby, Guy Victor, Hervieu-BègueMarsac, Marie, Garnier, Pierre, Accassat, Sandrine, Epinat, Magali, Varvat, Jérôme, Marinescu, Doïna, Triquenot-Bagan, Aude, Ozkul- Wermester, Ozlem, Philippeau, Frédéric, Olaru, Angel, Vieillart, Anne, Lannuzel, Annie, Demoly, Alice, Wolff, Valérie, Diaconu, Mihaela, Bataillard, Marc, Montoro, Francisco Macian, Faugeras, Frédéric, Gimenez, Laeticia, Abdallah-Lebeau, Françoise, Timsit, Serge, Viakhireva-Dovganyuk, Irina, Tirel-Badets, Anne, Merrien, François-Mathias, Goas, Philippe, Rouhart, François, Jourdain, Aurore, Guillon, Benoit, Hérissson, Fanny, Sevin-Allouet, Mathieu, Nasr, Nathalie, Olivot, Jean-Marc, Lecluse, Alderic, Marc, Guillaume, Touzé, Emmanuel, de la Sayette, Vincent, Apoil, Marion, Lin, Li, Cogez, Julien, Guettier, Sophie, Godefroy, Olivier, Lamy, Chantal, Bugnicourt, Jean-Marc, Taurin, Grégory, Mérienne, Marc, Gere, Julien, Chessak, Anne-Marie, Habet, Tarik, Ferrier, Anna, Bourgois, Nathalie, Minier, Dominique, Caillier-Minier, Marie, Contégal- Callier, Fabienne, Vion, Philippe, Vaschalde, Yvan, Amrani, Mohammed El, Emilie, Zuber, Mathieu, Bruandet, Marie, Join- Lambert, Claire, Garcia, Pierre-Yves, Serre, Isabelle, Faucheux, Jean-Marc, Radji, Fatia, Leca-Radu, Elena, Debroucker, Thomas, Cumurcuc, Rodica, Cakmak, Serkan, Peysson, Stéphane, Ellie, Emmanuel, Bernady, Patricia, Moulin, Thierry, Montiel, Paola, Revenco, Eugeniu, Decavel, Pierre, Medeiros, Elisabeth, Bouveret, Myriam, Louchart, Pierre, Vaduva, Claudia, Couvreur, Grégory, Sartori, Eric, Carpentier, Alnajar, Levasseur, Michèle, Louchart, Pierre, Faucheux, Jean-Marc, Neau, Philippe, Vandamme, Xavier, Meresse, Isabelle, Stantescu, Bataillard, Marc, Ozsancak, Canan, Beauvais, Katell, Auzou, Pascal, Amevigbe, Joséphine, Vuillemet, Francis, Dugay-Arentz, Marie-Hélène, Carelli, Gabriela, Martinez, Mikel, Maillet-Vioud, Marcel, Escaillas, Jean-Pierre, Chapuis, Stéphane, Tardy, Jean, Manchon, Eric, Varnet, Olivier, Kim, Yong-Jae, Chang, Yoonkyung, Song, Tae-Jin, Kim, Jong Sung, Han, Jung-Hoon, Noh, Kyung Chul, Lee, Eun-Jae, Kang, Dong-Wha, Kwon, Sun Uck, Kwon, Boseoung, Park, Seongho, Lee, Dongwhane, Kwon, Hyuk Sung, Jeong, Daeun, Lee, MinHwan, Kim, Joonggoo, Lee, Hanbin, Nam, Hyo Jung, Lee, Sang Hun, Kim, Bum Joon, Cha, Jae-kwan, Kim, DaeHyun, Kim, Rae Young, Sohn, Sang Wuk, Shim, Dong-Hyun, Lee, Hyungjin, Nah, Hyun-Wook, Sung, Sang Min, Lee, Kyung Bok, Yoon Lee, Jeong, Yoon, Jee Eun, Kim, Eung-Gyu, Seo, Jung Hwa, Kim, Yong-Won, Hwang, Yangha, Park, Man Seok, Kim, Joon-Tae, Choi, Kang-Ho, Nam, Hyo Suk, Heo, Ji Hoe, Kim, Young Dae, Hwang, In Gun, Park, Hyung Jong, Kim, Kyoung Sub, Baek, Jang Hyun, Song, Dong Beom, Yoo, Joon Sang, Park, Jong-Moo, Kwon, Ohyun, Lee, Woong-Woo, Lee, Jung-Ju, Kang, Kyusik, Kim, Byung Kun, Lim, Jae-Sung, Oh, Mi Sun, Yu, Kyung-Ho, Hong, Bora, Jang, Mihoon, Jang, Seyoung, Jin, Jung Eun, Kim, Jei, Jeong, Hye Seon, Hong, Keun Sik, Park, Hong Kyun, Cho, Yong Jin, Bang, Oh Young, Seo, Woo-Keun, and Chung, Jongwon

Published
2023
Full Text
View/download PDF

6. Endovascular Therapy or Medical Management Alone for Isolated Posterior Cerebral Artery Occlusion: A Multicenter Study

Author

Sabben, Candice, Charbonneau, Frédérique, Delvoye, François, Strambo, Davide, Heldner, Mirjam R., Ong, Elodie, Ter Schiphorst, Adrien, Henon, Hilde, Ben Hassen, Wagih, Agasse-Lafont, Thomas, Legris, Loïc, Sibon, Igor, Wolff, Valérie, Sablot, Denis, Elhorany, Mahmoud, Preterre, Cécile, Nehme, Nour, Soize, Sébastien, Weisenburger-Lile, David, Triquenot-Bagan, Aude, Mione, Gioia, Aignatoaie, Andreea, Papassin, Jérémie, Poll, Roxana, Béjot, Yannick, Carrera, Emmanuel, Garnier, Pierre, Michel, Patrik, Saliou, Guillaume, Mordasini, Pasquale, Berthezene, Yves, Costalat, Vincent, Bricout, Nicolas, Albers, Gregory W., Mazighi, Mikael, Turc, Guillaume, Seners, Pierre, Antonenko, Kateryna, Arquizan, Caroline, Benammar, Lynda, Boutet, Claire, Clarençon, Frédéric, Comby, Pierre-Olivier, Desal, Hubert, Detante, Olivier, Eugene, François, Gerardin, Emmanuel, Gory, Benjamin, Kremer, Stéphane, Ledure, Sylvain, Krug, Mathieu, Lapergue, Bertrand, Niclot, Philippe, Magni, Christophe, Obadia, Michael, Ozsancak, Canan, Pico, Fernando, Pilgram-Pastor, Sara, Pop, Raoul, Richard, Sébastien, Rosso, Charlotte, Savatovsky, Julien, Moulin, Solène, Tracol, Clément, and Zbinden, Martin

Published
2023
Full Text
View/download PDF

7. Effect of the COVID-19 pandemic on acute stroke reperfusion therapy: data from the Lyon Stroke Center Network

Author

Plumereau, Cécile, Cho, Tae-Hee, Buisson, Marielle, Amaz, Camille, Cappucci, Matteo, Derex, Laurent, Ong, Elodie, Fontaine, Julia, Rascle, Lucie, Riva, Roberto, Schiavo, David, Benhamed, Axel, Douplat, Marion, Bony, Thomas, Tazarourte, Karim, Tuttle, Célia, Eker, Omer Faruk, Berthezène, Yves, Ovize, Michel, Nighoghossian, Norbert, and Mechtouff, Laura

Published
2021
Full Text
View/download PDF

9. Collateral circulation assessment within the 4.5 h time window in patients with and without DWI/FLAIR MRI mismatch

Author

Berthezène, Yves, Eker, Omer, Makris, Nikolaos, Bettan, Maxime, Mansuy, Adeline, Chabrol, Aurélie, Mikkelsenm, Irene K., Hermier, Marc, Mechtouff, Laura, Ong, Elodie, Derex, Laurent, Berner, Lise-Prune, Ameli, Roxana, Pedraza, Salvador, Thomalla, Gotz, Østergaard, Leif, Baron, Jean-Claude, Cho, Tae-Hee, and Nighoghossian, Norbert

Published
2018
Full Text
View/download PDF

12. Benefit of Targeting a LDL (Low-Density Lipoprotein) Cholesterol <70 mg/dL During 5 Years After Ischemic Stroke

Author

Amarenco, Pierre, Kim, Jong S., Labreuche, Julien, Charles, Hugo, Giroud, Maurice, Lee, Byung-Chul, Mahagne, Marie-Hélène, Nighoghossian, Norbert, Gabriel Steg, Philippe, Vicaut, Éric, Bruckert, Eric, Touboul, Pierre-Jean, Leys, Didier, Béjot, Yannick, Lavallée, Philippa, Pico, Fernando, Touzé, Emmanuel, Ducrocq, Gregory, Abtan, Jérémy, Varenne, Olivier, Touboul, Pierre-Jean, Kemmel, Agnes, Syana, Fausta, Ledra, Manele, Nagasara, Tharani, Ledjeroud, Mervette, Samia, Bahous, Hadia, Hafirassou, Hazare, Benyoub, El Jaghouni, Ikrame, Yelles, Nessima, Zemouri, Sofia, Ladjeroud, Mervette, Kerai, Salim, In, Yun Jeong, Meseguer, Elena, Lavallée, Philippa C, Hobeanu, Cristina, Guidoux, Celine, Cabrejo, Lucie, Lapergue, Bertrand, Sabben, Candice, Gonzalez-Valcarcel, Jaime, Rigual, Ricardo, Sirimarco, Gaia, Martin-Bechet, Anna, Viedma, Elena, Avram, Ioan, Samson, Yves, Rosso, Charlotte, Crozier, Sophie, Leder, Sara, Léger, Anne, Deltour, Sandrine, Mutlu, Gurkan, Yger, Marion, Zavanone, Chiara, Baronnet, Flore, Pires, Christine, Lapergue, Bertrand, Wang, Adrien, Evrard, Serge, Tchikviladze, Maya, Bourdain, Frédéric, Lopez, Delphine, Pico, Fernando, de la Tour, Laetitia Bayon, Chadenat, Marie-Laure, Duong, Duc Long, Genty, Solène, Hirel, Catherine, Mutlu, Gurkan, Nifle, Chantal, Servan, Jérôme, Stanciu, Daniela, Sudacevschi, Veronica, Tir, Mélissa, Troussière, Anne-Cécile, Yeung, Jennifer, Zeghoudi, Anne-Céline, Tidafi-Bayou, Ikram, Lachaud, Sylvain, Cho, Tae-Hee, Mechtouff, Laura, Ritzenthaller, Thomas, Derex, Laurent, Albanesi, Carlo, Ong, Elodie, Benoit, Amandine, Berhoune, Nadia, Felix, Sandra, Esteban-Mader, Maud, Sibon, Igor, Kazadi, Annabelle, Rouanet, François, Renou, Pauline, Debruxelles, Sabrina, Poli, Mathilde, Sagnier, Sharmila, Mas, Jean-Louis, Domigo, Valérie, Lamy, Catherine, Bodiguel, Eric, Grimaud, Jérôme, Bohotin, Valentin, Obadia, Michael, Sabben, Candice, Morvan, Erwan, Rodier, Gilles, Vadot, Wilfried, Hénon, Hilde, Cordonnier, Charlotte, Dumont, Frédéric, Bodenant, Marie, Lucas, Christian, Moulin, Solène, Dequatre, Nelly, Alamowitch, Sonia, Muresan, Jean-Paul, Drouet, Thomas, Gallea, Magalie, Dalloz, Marie-Amélie, Delorme, Stephen, Yger, Marion, Béjot, Yannick, Loisel, Philippe, Bonnin, Carine, Bernigal, Virginie, Osseby, Guy Victor, Marsac, Marie Hervieu-Bègue, Garnier, Pierre, Accassat, Sandrine, Epinat, Magali, Varvat, Jérôme, Marinescu, Doïna, Triquenot-Bagan, Aude, Ozkul-Wermester, Ozlem, Philippeau, Frédéric, Olaru, Angel, Vieillart, Anne, Lannuzel, Annie, Demoly, Alice, Wolff, Valérie, Diaconu, Mihaela, Bataillard, Marc, Montoro, Francisco Macian, Faugeras, Frédéric, Gimenez, Laeticia, Abdallah-Lebeau, Françoise, Timsit, Serge, Viakhireva-Dovganyuk, Irina, Tirel-Badets, Anne, Merrien, François-Mathias, Goas, Philippe, Rouhart, François, Jourdain, Aurore, Guillon, Benoit, Hérissson, Fanny, Sevin-Allouet, Mathieu, Nasr, Nathalie, Olivot, Jean-Marc, Lecluse, Alderic, Marc, Guillaume, Touzé, Emmanuel, de la Sayette, Vincent, Apoil, Marion, Lin, Li, Cogez, Julien, Guettier, Sophie, Godefroy, Olivier, Lamy, Chantal, Bugnicourt, Jean-Marc, Taurin, Grégory, Mérienne, Marc, Gere, Julien, Chessak, Anne-Marie, Habet, Tarik, Ferrier, Anna, Bourgois, Nathalie, Minier, Dominique, Caillier-Minier, Marie, Contégal-Callier, Fabienne, Vion, Philippe, Vaschalde, Yvan, El Amrani, Emilie, Mohammed, Zuber, Mathieu, Bruandet, Marie, Join-Lambert, Claire, Garcia, Pierre-Yves, Serre, Isabelle, Faucheux, Jean-Marc, Radji, Fatia, Leca-Radu, Elena, Debroucker, Thomas, Cumurcuc, Rodica, Cakmak, Serkan, Peysson, Stéphane, Ellie, Emmanuel, Bernady, Patricia, Moulin, Thierry, Montiel, Paola, Revenco, Eugeniu, Decavel, Pierre, Medeiros, Elisabeth, Bouveret, Myriam, Louchart, Pierre, Vaduva, Claudia, Couvreur, Grégory, Sartori, Eric, Alnajar-Carpentier, Eric, Levasseur, Michèle, Louchart, Pierre, Neau, Jean-Philippe, Vandamme, Xavier, Meresse, Isabelle, Stantescu, Bataillard, Marc, Ozsancak, Canan, Beauvais, Katell, Auzou, Pascal, Amevigbe, Joséphine, Vuillemet, Francis, Dugay-Arentz, Marie-Hélène, Carelli, Gabriela, Martinez, Mikel, Maillet-Vioud, Marcel, Escaillas, Jean-Pierre, Chapuis, Stéphane, Tardy, Jean, Manchon, Eric, Varnet, Olivier, Kim, Yong-Jae, Chang, Yoonkyung, Song, Tae-Jin, Han, Jung-Hoon, Noh, Kyung Chul, Lee, Eun-Jae, Kang, Dong-Wha, Kwon, Sun Uck, Kwon, Boseoung, Park, Seongho, Lee, Dongwhane, Kwon, Hyuk Sung, Jeong, Daeun, Lee, MinHwan, Kim, Joonggoo, Lee, Hanbin, Nam, Hyo Jung, Lee, Sang Hun, Kim, Bum Joon, Cha, Jae-kwan, Kim, DaeHyun, Young Kim, Rae, Sohn, Sang Wuk, Shim, Dong-Hyun, Lee, Hyungjin, Nah, Hyun-Wook, Sung, Sang Min, Lee, Kyung Bok, Lee, Jeong Yoon, Yoon, Jee Eun, Kim, Eung-Gyu, Seo, Jung Hwa, Kim, Yong-Won, Hwang, Yangha, Park, Man Seok, Kim, Joon-Tae, Choi, Kang-Ho, Nam, Hyo Suk, Heo, Ji Hoe, Kim, Young Dae, Hwang, In Gun, Park, Hyung Jong, Kim, Kyoung Sub, Baek, Jang Hyun, Song, Dong Beom, Yoo, Joon Sang, Park, Jong-Moo, Kwon, Ohyun, Lee, Woong-Woo, Lee, Jung-Ju, Kang, Kyusik, Kim, Byung Kun, Lim, Jae-Sung, Oh, Mi Sun, Yu, Kyung-Ho, Hong, Bora, Jang, Mihoon, Jang, Seyoung, Jin, Jung Eun, Kim, Jei, Jeong, Hye Seon, Hong, Keun Sik, Park, Hong Kyun, Cho, Yong Jin, Bang, Oh Young, Seo, Woo-Keun, and Chung, Jongwon

Published
2020
Full Text
View/download PDF

17. In vivo targeting and multimodal imaging of cerebral amyloid-β aggregates using hybrid GdF3 nanoparticles.

Author

Lerouge, Frédéric, Ong, Elodie, Rositi, Hugo, Mpambani, Francis, Berner, Lise-Prune, Bolbos, Radu, Olivier, Cécile, Peyrin, Françoise, Apputukan, Vinu K, Monnereau, Cyrille, Andraud, Chantal, Chaput, Frederic, Berthezène, Yves, Braun, Bettina, Jucker, Mathias, Åslund, Andreas KO, Nyström, Sofie, Hammarström, Per, R Nilsson, K Peter, and Lindgren, Mikael

Abstract

Aim: To propose a new multimodal imaging agent targeting amyloid-β (Aβ) plaques in Alzheimer's disease. Materials & methods: A new generation of hybrid contrast agents, based on gadolinium fluoride nanoparticles grafted with a pentameric luminescent-conjugated polythiophene, was designed, extensively characterized and evaluated in animal models of Alzheimer's disease through MRI, two-photon microscopy and synchrotron x-ray phase-contrast imaging. Results & conclusion: Two different grafting densities of luminescent-conjugated polythiophene were achieved while preserving colloidal stability and fluorescent properties, and without affecting biodistribution. In vivo brain uptake was dependent on the blood–brain barrier status. Nevertheless, multimodal imaging showed successful Aβ targeting in both transgenic mice and Aβ fibril-injected rats. The design and study of a new contrast agent targeting amyloid-β (Aβ) plaques in Alzheimer's disease (AD) is proposed. Aβ plaques are the earliest pathological sign of AD, silently appearing in the brain decades before the symptoms of the disease are manifested. While current detection of Aβ plaques is based on nuclear medicine (a technique using a radioactive agent), a different kind of contrast agent is here evaluated in animal models of AD. The contrast agent consists of a nanoparticle made of gadolinium and fluorine ions (core), and decorated with a molecule previously shown to bind to Aβ plaques (grafting). The core is detectable with MRI and x-ray imaging, while the grafting molecule is detectable with fluorescence imaging, thus allowing different imaging methods to be combined to study the pathology. In this work, the structure, stability and properties of the contrast agent have been verified in vitro (in tubes and on brain sections). Then the ability of the contrast agent to bind to Aβ plaques and provide a detectable signal in MRI, x-ray or fluorescence imaging has been demonstrated in vivo (in rodent models of AD). This interdisciplinary research establishes the proof of concept that this new class of versatile agent contrast can be used to target pathological processes in the brain. New multimodal contrast agent developed at University of Lyon: a functionalized gadolinium-based nanoparticle shows successful targeting of amyloid-β fibrils and in vivo detection with two-photon microscopy and MRI in animal models of Alzheimer's disease. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

18. MRI coupled with clinically-applicable iron oxide nanoparticles reveals choroid plexus involvement in a murine model of neuroinflammation

Author

Hubert, Violaine, Dumot, Chloé, Ong, Elodie, Amaz, Camille, Canet-Soulas, Emmanuelle, Chauveau, Fabien, Wiart, Marlène, Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Institut National de la Recherche Agronomique (INRA), Hospices Civils de Lyon (HCL), Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé (CREATIS), Université Jean Monnet [Saint-Étienne] (UJM)-Hospices Civils de Lyon (HCL)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d’Investigation Clinique de Lyon (CIC de Lyon), Centre de recherche en neurosciences de Lyon (CRNL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), French National Research Agency (ANR) [ANR-15-CE18-0026-01], University Claude Bernard Lyon 1 (UCBL), within the program 'Investissements d'Avenir' [ANR-16-RHUS-0009], Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), ANR, ANR-15-CE18-0026,NanoBrain,Imagerie de l’inflammation cérébrale dans l’AVC ischémique : développement d’une sonde nanoparticulaire multimodale & méthodes d’imagerie cérébrale(2015), ANR: 16-RHUS-0009,MARVELOUS,MARVELOUS(2016), Wiart, Marlene, Imagerie de l'inflammation cérébrale dans l'AVC ischémique : développement d'une sonde nanoparticulaire multimodale & méthodes d'imagerie cérébrale - - NanoBrain2015 - ANR-15-CE18-0026 - AAPG2015 - VALID, MARVELOUS - - MARVELOUS2016 - ANR-16-RHUS-0009 - RHUS - VALID, Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), ANR-15-CE18-0026,NanoBrain,Imagerie de l'inflammation cérébrale dans l'AVC ischémique : développement d'une sonde nanoparticulaire multimodale & méthodes d'imagerie cérébrale(2015), and ANR-16-RHUS-0009,MARVELOUS,MARVELOUS(2016)

Subjects
Imaging techniques and agents, Lipopolysaccharides, Male, [SDV.BIO]Life Sciences [q-bio]/Biotechnology, [SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imaging, Contrast Media, Metal Nanoparticles, lcsh:Medicine, Ferric Compounds, Article, Translational Research, Biomedical, Mice, Neurological models, Animals, Humans, lcsh:Science, ComputingMilieux_MISCELLANEOUS, lcsh:R, Translational research, Magnetic Resonance Imaging, Mice, Inbred C57BL, Disease Models, Animal, [SDV.IB.IMA] Life Sciences [q-bio]/Bioengineering/Imaging, Choroid Plexus, Imaging the immune system, lcsh:Q, Neurogenic Inflammation, Injections, Intraperitoneal
Abstract

International audience; Choroid plexus (ChPs) are involved in the early inflammatory response that occurs in many brain disorders. However, the activation of immune cells within the ChPs in response to neuroinflammation is still largely unexplored in-vivo. There is therefore a crucial need for developing imaging tool that would allow the non-invasive monitoring of ChP involvement in these diseases. Magnetic resonance imaging (MRI) coupled with superparamagnetic particles of iron oxide (SPIO) is a minimally invasive technique allowing to track phagocytic cells in inflammatory diseases. Our aim was to investigate the potential of ultrasmall SPIO (USPIO)-enhanced MRI to monitor ChP involvement in-vivo in a mouse model of neuroinflammation obtained by intraperitoneal administration of lipopolysaccharide. Using high resolution MRI, we identified marked USPIO-related signal drops in the ChPs of animals with neuroinflammation compared to controls. We confirmed these results quantitatively using a 4-points grading system. Ex-vivo analysis confirmed USPIO accumulation within the ChP stroma and their uptake by immune cells. We validated the translational potential of our approach using the clinically-applicable USPIO Ferumoxytol. MR imaging of USPIO accumulation within the ChPs may serve as an imaging biomarker to study ChP involvement in neuroinflammatory disorders that could be applied in a straightforward way in clinical practice.

Published
2019

21. A lower admission level of interleukin-6 is associated with first-pass effect in ischemic stroke patients.

Author

Mechtouff, Laura, Bochaton, Thomas, Paccalet, Alexandre, Da Silva, Claire Crola, Buisson, Marielle, Amaz, Camille, Derex, Laurent, Ong, Elodie, Berthezene, Yves, Dufay, Nathalie, Ovize, Michel, Mewton, Nathan, Tae-Hee Cho, Nighoghossian, Norbert, and Eker, Omer F.

Subjects
INTERLEUKINS, BIOMARKERS, C-reactive protein, CONFIDENCE intervals, ISCHEMIC stroke, INFLAMMATION, MULTIVARIATE analysis, PATIENTS, MAGNETIC resonance imaging, HOSPITAL admission & discharge, VEIN surgery, TREATMENT effectiveness, THROMBECTOMY, ENZYME-linked immunosorbent assay, STROKE patients, DESCRIPTIVE statistics, LOGISTIC regression analysis, ODDS ratio
Abstract

Background First-pass effect (FPE) defined as a complete or near-complete reperfusion achieved after a single thrombectomy pass is predictive of favorable outcome in acute ischemic stroke (AIS) patients. We aimed to assess whether admission levels of inflammatory markers are associated with FPE. Methods HIBISCUS-STROKE (CoHort of Patients to Identify Biological and Imaging markerS of CardiovascUlar Outcomes in Stroke) includes AIS patients with large vessel occlusion treated with mechanical thrombectomy following brain MRI. C-reactive protein, interleukin (IL)-6, IL-8, IL-10, monocyte chemoattractant protein-1, soluble tumor necrosis factor receptor I, soluble form suppression of tumorigenicity 2, matrix metalloproteinase-9 (MMP-9), soluble P-selectin, and vascular cellular adhesion molecule-1 were measured in admission sera using an ELISA assay. FPE was defined as a complete or near-complete reperfusion (thrombolysis in cerebral infarction scale (TICI) 2c or 3) after the first pass. A multivariate logistic regression analysis was performed to assess independent factors associated with FPE. Results A total of 151 patients were included. Among them, 43 (28.5%) patients had FPE. FPE was associated with low admission levels of IL-6, MMP-9, and platelet count, an older age, lack of hypertension, lack of tandem occlusion, a shorter thrombus length, and a reduced procedural time. Following multivariate analysis, a low admission level of IL-6 was associated with FPE (OR 0.66, 95% CI 0.46 to 0.94). Optimal cut-off of IL-6 level for distinguishing FPE from non-FPE was 3.0 pg/mL (sensitivity 92.3%, specificity 42.3%). Conclusion A lower admission level of IL-6 is associated with FPE. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

22. Does the Brush-Sign Reflect Collateral Status and DWI-ASPECTS in Large Vessel Occlusion?

Author

Rascle, Lucie, Bani Sadr, Alexandre, Amaz, Camille, Mewton, Nathan, Buisson, Marielle, Hermier, Marc, Ong, Elodie, Fontaine, Julia, Derex, Laurent, Berthezène, Yves, Eker, Omer Faruk, Cho, Tae-Hee, Nighoghossian, Norbert, and Mechtouff, Laura

Subjects
DIGITAL subtraction angiography, INTERNAL carotid artery, ISCHEMIC stroke, CEREBRAL arteries
Abstract

Introduction: The relevance of the brush-sign remained poorly documented in large vessel occlusion (LVO). We aimed to assess the relationship between the brush-sign and collateral status and its potential impact on baseline diffusion-weighted imaging–Alberta Stroke Program Early Computed Tomography Score (DWI-ASPECTS) in acute ischemic stroke (AIS) patients eligible to mechanical thrombectomy (MT). Methods: Consecutive patients admitted in the Lyon Stroke Center with anterior circulation AIS due to intracranial internal carotid artery (ICA) and/or M1 or M2 segment of the middle cerebral artery (MCA) occlusion eligible for MT were included. The brush-sign was assessed on T2-gradient-echo MRI. Collateral status was assessed on digital subtraction angiography according to the American Society of Interventional and Therapeutic Neuroradiology/Society of Interventional Radiology (ASITN/SIR) score. Results: In this study, 504 patients were included, among which 171 (33.9%) patients had a brush-sign. Patients with a brush-sign more frequently had a poor collateral status [72 (42.1%) vs. 103 (30.9%); p = 0.017]. In univariable analysis, a DWI-ASPECTS < 7 was associated with a brush sign. Following multivariable analysis, the brush-sign no longer affected DWI-ASPECTS < 7 while the latter remained associated with younger age [odds ratio (OR) 0.97, 95% CI.96–0.99], male sex (OR 1.79, 95% CI 1.08–2.99), a higher National Institutes of Health Stroke Scale (NIHSS) score (OR 1.16, 95% CI 1.1–1.21), a poor collateral status (OR 9.35, 95% CI 5.59-16.02), MCA segment (OR 2.54, 95% CI 1.25–5.38), and intracranial ICA (OR 3.01, 95% CI 1.16–8) occlusion. Conclusions and Relevance: The brush-sign may be a marker of poor collateral status but did not independently predict a lower DWI-ASPECTS. Clinical Trial Registration: ClinicalTrials.gov, identifier: NCT04620642. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

23. Temporal trends in reperfusion therapy for patients with acute ischemic stroke.

Author

El Khoury, Carlos, Aboa-Eboule, Corine, Fraticelli, Laurie, Claustre, Clément, Bischoff, Magali, Blanc-Lasserre, Karine, Buisson, Marielle, Cakmak, Serkan, Tee-hi Cho, Ferroud-Plattet, Bruno, Guerrier, Olivier, Philippeau, Frédéric, Serre, Patrice, Mechtouff, Laura, Nighoghossian, Norbert, Ruzteroltz, Thierry, Vallet, Anne-Evelyne, Ong, Elodie, and Derex, Laurent

Published
2022
Full Text
View/download PDF

24. Clinical imaging of choroid plexus in health and in brain disorders: a mini-review

Author

Hubert, Violaine, Chauveau, Fabien, Dumot, Chloé, Ong, Elodie, Berner, Lise-Prune, Canet-Soulas, Emmanuelle, Ghersi-Egea, Jean-François, Wiart, Marlène, Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Institut National de la Recherche Agronomique (INRA), Centre de recherche en neurosciences de Lyon (CRNL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé (CREATIS), Université Jean Monnet [Saint-Étienne] (UJM)-Hospices Civils de Lyon (HCL)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hospices Civils de Lyon (HCL), rench National Research Agency (ANR) [ANR-15-CE18-0026-0], [ANR-10-IBHU-0003], [ANR-15-CE17-0020-0], [ANR-16-RHUS-0009], Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center (CRNL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), ANR-15-CE18-0026,NanoBrain,Imagerie de l'inflammation cérébrale dans l'AVC ischémique : développement d'une sonde nanoparticulaire multimodale & méthodes d'imagerie cérébrale(2015), ANR-16-RHUS-0009,MARVELOUS,MARVELOUS(2016), ANR-15-CE17-0020,CYCLOPS,CYCLOsporine A : effet neuroprotecteur dans un modèle Primate de Stroke en imagerie(2015), CarMeN, laboratoire, Imagerie de l'inflammation cérébrale dans l'AVC ischémique : développement d'une sonde nanoparticulaire multimodale & méthodes d'imagerie cérébrale - - NanoBrain2015 - ANR-15-CE18-0026 - AAPG2015 - VALID, MARVELOUS - - MARVELOUS2016 - ANR-16-RHUS-0009 - RHUS - VALID, and CYCLOsporine A : effet neuroprotecteur dans un modèle Primate de Stroke en imagerie - - CYCLOPS2015 - ANR-15-CE17-0020 - AAPG2015 - VALID

Subjects
choroid plexus, imaging, central nervous system, blood-CSF barrier, inflammation, neurological disease, [SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imaging, Mini Review, Neurosciences, maladie neurologique, imagerie moléculaire, système nerveux central, [SDV.IB.IMA] Life Sciences [q-bio]/Bioengineering/Imaging, Neurons and Cognition, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], [SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], ComputingMilieux_MISCELLANEOUS, Neuroscience
Abstract

The choroid plexuses (ChPs) perform indispensable functions for the development, maintenance and functioning of the brain. Although they have gained considerable interest in the last years, their involvement in brain disorders is still largely unknown, notably because their deep location inside the brain hampers non-invasive investigations. Imaging tools have become instrumental to the diagnosis and pathophysiological study of neurological and neuropsychiatric diseases. This review summarizes the knowledge that has been gathered from the clinical imaging of ChPs in health and brain disorders not related to ChP pathologies. Results are discussed in the light of pre-clinical imaging studies. As seen in this review, to date, most clinical imaging studies of ChPs have used disease-free human subjects to demonstrate the value of different imaging biomarkers (ChP size, perfusion/permeability, glucose metabolism, inflammation), sometimes combined with the study of normal aging. Although very few studies have actually tested the value of ChP imaging biomarkers in patients with brain disorders, these pioneer studies identified ChP changes that are promising data for a better understanding and follow-up of diseases such as schizophrenia, epilepsy and Alzheimer's disease. Imaging of immune cell trafficking at the ChPs has remained limited to pre-clinical studies so far but has the potential to be translated in patients for example using MRI coupled with the injection of iron oxide nanoparticles. Future investigations should aim at confirming and extending these findings and at developing translational molecular imaging tools for bridging the gap between basic molecular and cellular neuroscience and clinical research.

Published
2019

25. Post-Thrombolysis Recanalization in Stroke Referrals for Thrombectomy

Author

Seners, Pierre, Turc, Guillaume, Naggara, Olivier, Hénon, Hilde, Piotin, Michel, Arquizan, Caroline, Cho, Tae-Hee, Narata, Ana-Paula, Lapergue, Bertrand, Richard, Sébastien, Legrand, Laurence, Bricout, Nicolas, Blanc, Raphaël, Dargazanli, Cyril, Gory, Benjamin, Debiais, Séverine, Tisserand, Marie, Bracard, Serge, Leclerc, Xavier, Obadia, Michael, Costalat, Vincent, Berner, Lise-Prune, Cottier, Jean-Philippe, Consoli, Arturo, Ducrocq, Xavier, Mas, Jean-Louis, Oppenheim, Catherine, Baron, Jean-Claude, Abrivard, Marie, Alamowitch, Sonia, Ben Hassen, Wagih, Berthezène, Yves, Blanc-Lasserre, Karine, Boulin, Anne, Boulouis, Grégoire, Bouly, Stephane, Bourdain, Frédéric, Calvet, David, Charron, Vladimir, Chbicheb, Mohamed, Condette-Auliac, Stéphanie, Corabianu, Ovide, Cordonnier, Charlotte, Coskun, Oguzhan, De Broucker, Thomas, Decroix, Jean-Pierre, Di Maria, Federico, Evrard, Serge, Fissellier, Mathieu, Girard, Isabelle, Lalu, Thibault, Le Coz, Patrick, Le Guen, Morgan, Ille, Olivier, Leys, Didier, Magni, Christophe, Manchon, Eric, Mazighi, Mikael, Mounier-Vehier, François, Moynier, Marinette, Muresan, Ioan-Paul, Nighoghossian, Norbert, Ong, Elodie, Ozsancak, Canan, Philippeau, Frédéric, Pico, Fernando, Rodesch, Georges, Rosolacci, Thierry, Sabben, Candice, Sablot, Denis, Tassan, Philippe, Tchikviladze, Maya, Turjman, Francis, Vallet, Anne-Evelyne, Wang, Adrien, Zins, Marc, Zuber, Mathieu, Centre Hospitalier Sainte Anne [Paris], Institut de psychiatrie et neurosciences (U894 / UMS 1266), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Département de neurologie[Lille], Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Fondation Ophtalmologique Adolphe de Rothschild [Paris], Département de neurologie [Montpellier], Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Gui de Chauliac [Montpellier]-Université de Montpellier (UM), Cerebrovascular Unit [Lyon], Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Service de neuroradiologie [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Hôpital Foch [Suresnes], Service de neurologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Services de neuroradiologie [Lille], Hôpital Roger Salengro-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Département de Neuroradiologie[Montpellier], Département de neuroradiologie diagnostique et thérapeutique [CHRU Nancy], Université de Montpellier (UM), Hospices Civils de Lyon (HCL), Centre hospitalier régional Metz-Thionville (CHR Metz-Thionville), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Département de neurologie [Lille], Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Gui de Chauliac [CHU Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université de Montpellier (UM), Hôpital Roger Salengro [Lille]-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Imagerie Adaptative Diagnostique et Interventionnelle (IADI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), and Hôpital Gui de Chauliac [Montpellier]-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Université de Montpellier (UM)

Subjects
[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, thrombectomy, incidence, magnetic resonance imaging, fibrinolysis, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], stroke
Abstract

International audience; Background and Purpose—Whether all acute stroke patients with large vessel occlusion need to undergo intravenous thrombolysis before mechanical thrombectomy (MT) is debated as (1) the incidence of post-thrombolysis early recanalization (ER) is still unclear; (2) thrombolysis may be harmful in patients unlikely to recanalize; and, conversely, (3) transfer for MT may be unnecessary in patients highly likely to recanalize. Here, we determined the incidence and predictors of post-thrombolysis ER in patients referred for MT and derive ER prediction scores for trial design. Methods—Registries from 4 MT-capable centers gathering patients referred for MT and thrombolyzed either on site (mothership) or in a non MT-capable center (drip-and-ship) after magnetic resonance– or computed tomography–based imaging between 2015 and 2017. ER was identified on either first angiographic run or noninvasive imaging. In the magnetic resonance imaging subsample, thrombus length was determined on T2*-based susceptibility vessel sign. Independent predictors of no- ER were identified using multivariable logistic regression models, and scores were developed according to the magnitude of regression coefficients. Similar registries from 4 additional MT-capable centers were used as validation cohort. Results—In the derivation cohort (N=633), ER incidence was ≈20%. In patients with susceptibility vessel sign (n=498), no-ER was independently predicted by long thrombus, proximal occlusion, and mothership paradigm. A 6-point score derived from these variables showed strong discriminative power for no-ER (C statistic, 0.854) and was replicated in the validation cohort (n=353; C statistic, 0.888). A second score derived from the whole sample (including negative T2* or computed tomography–based imaging) also showed good discriminative power and was similarly validated. Highest grades on both scores predicted no-ER with >90% specificity, whereas low grades did not reliably predict ER. Conclusions—The substantial ER rate underlines the benefits derived from thrombolysis in bridging populations. Both prediction scores afforded high specificity for no-ER, but not for ER, which has implications for trial design.

Published
2018

28. EHRA/ESC LEFT ATRIAL APPENDAGE CLOSURE (LAAC) CANDIDATES AT DISCHARGE AFTER A STROKE ASSOCIATED WITH ATRIAL FIBRILLATION (AF): 12 MONTHS OUTCOME. THE WATCH-AF REGISTRY

Author

Ong, Elodie

Abstract

Background and objective: Because of frailty, cognitive impairment, co-morbidities, patient refusal, or perceived low risk of stroke or high bleeding risk, many patients with stroke and AF cannot be discharged on long-term oral anticoagulant (LTOAC). Among them, the proportion of candidate for LAAC and their 12-month outcome is not well known.Method: Consecutive patients admitted within 24 hours of symptom onset of an acute stroke associated with AF in two stroke centers had systematic data collection (e.g., CHADSVASC, HASBLED) at 6 and 1 months before stroke, at admission, discharge, 2 and 8 days, 3, 12 months post stroke. The primary endpoint was death or dependency (mRS>3). Potential candidates for LAAC were based on ERHA/ESC recommendations.Results: Among 400 enrolled patients, 30 patients died before discharge. Among 370 patients alive at discharge, 131 patients were not discharged on LTOAC, including 39/370 (10.5%) who were EHRA/ESC LAAC indication. At 12 months, death or dependency occurred in 24.3% in 239 patients discharged on LTOAC, as compared to 54.7% in patients not discharged on LTOAC and not ERHA/ESC candidate for LAAC, and to 25.9% in patients not discharged on LTOAC and with ERHA/ESC LAAC indication (p

Published
2017

30. Impact of the Thrombectomy Trials on the Management and Outcome of Large Vessel Stroke: Data From the Lyon Stroke Center.

Author

Viannay, Louis, Haesebaert, Julie, Florin, Fannie, Riva, Roberto, Mechtouff, Laura, Gory, Benjamin, Ong, Elodie, Labeyrie, Paul-Emile, Derex, Laurent, Hermier, Marc, Chamard, Leila, Berner, Lise-Prune, Ameli, Roxana, Berthezène, Yves, Turjman, Francis, Nighoghossian, Norbert, and Cho, Tae-Hee

Subjects
STROKE patients, CLINICAL trials, BLOOD coagulation disorders
Abstract

Introduction: Randomized trials (RT) have recently validated the superiority of thrombectomy over standard medical care, including intravenous thrombolysis (IVT). However, data on their impact on routine clinical care remains scarce. Methods: Using a prospective observational registry, we assessed: (1) the clinical and radiological characteristics of all consecutive patients treated with thrombectomy; (2) the outcome of all patients with M1 occlusion (treated with thrombectomy or IVT alone). Two periods were compared: before (2013–2014) and after (2015–2016) the publication of RT. Results: Endovascular procedures significantly increased between the two periods (N = 82 vs. 314, p < 0.0001). In 2015–2016, patients were older (median [IQR]: 69 [57-80]; vs. 66 [53-74]; p = 0.008), had shorter door-to-clot times (69 [47-95]; vs. 110 [83-155]; p < 0.0001) resulting in a trend toward shorter delay from symptom onset to reperfusion (232 [185-300]; vs. 250 [200-339]; p = 0.1), with higher rates of reperfusion (71 vs. 48%; p = 0.0001). Conversely, no significant differences in baseline NIHSS scores, ASPECTS, delay to IVT or intracranial hemorrhage were found. In 2015–2016, patients with M1 occlusion were treated with thrombectomy more often than in 2013–2014 (87 vs. 32%, respectively; p < 0.0001), with a significant improvement in clinical outcome (shift analysis, lower modified Rankin scale scores: OR = 1.68; 95% CI: 1.10–2.57; p = 0.017). Conclusion: Following the publication of RT, thrombectomy was rapidly implemented with significant improvements in intrahospital delay and reperfusion rates. Treatment with thrombectomy increased with better clinical outcomes in patients with M1 occlusion. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

31. Effect of Cyclosporine on Lesion Growth and Infarct Size Within the White and Gray Matter.

Author

Ong, Elodie, Mewton, Nathan, Bouvier, Julien, Chauveau, Fabien, Ritzenthaler, Thomas, Mechtouff, Laura, Derex, Laurent, Buisson, Marielle, Berthezène, Yves, Ovize, Michel, Nighoghossian, Norbert, and Tae-Hee Cho

Subjects
CYCLOSPORINE, GRAY matter (Nerve tissue), ISCHEMIA
Abstract

Background: In a recent trial, cyclosporine A (CsA) failed to reduce infarct size in acute stroke patients treated with intravenous thrombolysis. White matter (WM) and gray matter (GM) may have distinct vulnerability to ischemia and response to therapy. Using final infarct size and lesion growth as endpoints, our objectives were to (1) investigate any tissue-specific effect of CsA and (2) compare WM and GM response to thrombolysis. Materials and methods: We analyzed 84 patients from the randomized and placebocontrolled CsA-Stroke trial, who underwent MRI both on admission and at 1 month. Lesion growth was defined voxel-wise as infarcted tissue at 1 month with no visible lesion on baseline diffusion-weighted imaging. After automatic segmentation of GM/WM, final infarct size and lesion growth were compared within the GM and WM. Results: Occlusion level was distal (>M1) in 51% of cases. No significant difference in GM/WM proportions was observed within final infarcts between treatment groups (P = 0.21). Infarct size within the GM or WM was similar between the CsA and control groups [GM: 9.2 (2.4; 22.8) with CsA vs 8.9 (3.7; 28.4) mL with placebo, P = 0.74; WM: 9.9 (4.7; 25.4) with CsA vs 14.1 (5.6; 34.1) mL with placebo, P = 0.26]. There was no significant effect of CsA on lesion growth in either the GM or WM. Pooling all patients, a trend for increased relative lesion growth in WM compared to GM was observed [49.0% (14.7; 185.7) vs 43.1% (15.4; 117.1), respectively; P = 0.12]. Conclusion: No differential effect of CsA was observed between WM and GM. Pooling all patients, a trend toward greater lesion growth in WM was observed. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

32. MRI Profile and Collateral Status in Patients with a Transient Ischemic Attack and an Intracranial Artery Occlusion.

Author

Ong, Elodie, Derex, Laurent, Mechtouff, Laura, Cho, Tae Hee, Nighoghossian, Norbert, Chamard, Leila, Eker, Omer, Berthezene, Yves, and Buisson, Marielle

Subjects
*COLLATERAL circulation, *BLOOD circulation, *INTRACRANIAL aneurysms, *CEREBROVASCULAR disease, *INTRACRANIAL arterial diseases
Abstract

Background and Purpose: Transient ischemic attack may rarely reveal an intracranial artery occlusion. We analyzed acute magnetic resonance imaging (MRI) patterns and early outcome after reperfusion therapy in these cases.Method: Clinical and imaging data were taken retrospectively from our comprehensive stroke center registry. Two MRI patterns were determined. Pattern A: full mismatch with negative diffusion-weighted imaging (DWI) and perfusion defect. Pattern B: large mismatch with positive DWI and perfusion defect. MRI-derived collateral flow maps were automatically generated from the raw of dynamic susceptibility contrast MRI. Patients were treated either by recombinant tissue plasminogen activator (rtPA) alone or in combination with mechanical thrombectomy.Results: From October 1, 2010 to May 15, 2016, 1,019 patients were admitted and treated by t-PA within 4.5 hours of stroke onset of them; 14 had a transient ischemic attack (TIA) within the 6 hours preceding MRI. Perfusion imaging was performed in 11 patients. An arterial occlusion was found in all of them, 11 patients had a distal anterior circulation occlusion, whereas 3 patients (21%) had a proximal occlusion. According to MRI, 6 patients showed pattern A, whereas 5 patients had pattern B. Good collaterals were observed in 10 patients (6 patients with grade 3 and 4 patients with grade 4), whereas 1 patient had poor collaterals (grade 2). The day 1 National Institutes of Health Stroke Scale median was 0. Modified Rankin Scale median at 3 months was 0.Conclusion: TIAs may reveal acute intracranial artery occlusion. Acute MRI may able to assist in therapeutic decision. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

33. Cyclosporine A, a Potential Therapy of Ischemic Reperfusion Injury. A Common History for Heart and Brain.

Author

Nighoghossian, Norbert, Ovize, Michel, Mewton, Nathan, Ong, Elodie, and Cho, Tae-Hee

Subjects
CYCLOSPORINE, TREATMENT of reperfusion injuries, IMMUNOSUPPRESSIVE agents
Abstract

Background: Ischemic stroke (IS) and acute myocardial infarction require emergency reperfusion tissue in order to improve functional outcome. Intra-arterial thrombectomy recently showed very encouraging improvement in IS patients' outcome. However, endovascular methods enhancing reperfusion may expose patients to increase in ischemic reperfusion injury. Experimental evidence indicates that brain ischemic reperfusion injury may be attenuated by ischemic pre- and post-conditioning. The opening of mitochondrial permeability transition pore plays a critical role in the onset of reperfusion damage. This mechanism can be inhibited by immunosuppressive drugs like cyclosporine A (CsA). Summary: In this review, we present existing experimental and clinical data suggesting that conditioning interventions may prevent brain ischemic reperfusion injury and future challenge for neuroprotection by CsA in acute IS. Key Messages: The concept of conditioning has been recently investigated clinically but to a lesser extent in the realm of IS. Recent experimental and phase II clinical research has suggested potential neuroprotective properties of cyclosporine; however, further larger clinical trials are needed to demonstrate that CsA improves clinical outcome in acute IS patients. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

37. Inflammatory profile and white matter hyperintensity burden in acute ischemic stroke patients.

Author

Rascle, Lucie, Nighoghossian, Norbert, Cho, Tae-Hee, Bochaton, Thomas, Paccalet, Alexandre, Crola Da Silva, Claire, Buisson, Marielle, Amaz, Camille, Fontaine, Julia, Ong, Elodie, Derex, Laurent, Berthezene, Yves, Eker, Omer Faruk, Mewton, Nathan, Ovize, Michel, and Mechtouff, Laura

Subjects
*STROKE patients, *WHITE matter (Nerve tissue), *ISCHEMIC stroke, *CEREBRAL small vessel diseases
Abstract

Inflammation is involved in small vessel disease (SVD). We aim to clarify whether inflammation related to white matter hyperintensities (WMH), a key component of SVD, may affect the inflammatory response in acute ischemic stroke (AIS) patients. For this, we sequentially measured 10 circulating inflammatory markers and assessed WMH burden on admission MRI in AIS patients treated with thrombectomy. Of 149 patients, 57 (38.3%) had a high WMH burden (Fazekas≥3). A high WMH burden was associated with 4 markers levels but this association did not remain following multivariable analyses. WMH burden is not associated with a specific inflammatory profile in AIS. [Display omitted] • 57 (38.3%) patients had a high white matter hyperintensity (WMH) burden (Fazekas≥3). • Univariable analysis showed an association between 4 markers levels and WMH burden. • None of these associations remained following multivariable analysis. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

38. In vivo targeting and multimodal imaging of cerebral amyloid-β aggregates using hybrid GdF 3 nanoparticles.

Author

Lerouge F, Ong E, Rositi H, Mpambani F, Berner LP, Bolbos R, Olivier C, Peyrin F, Apputukan VK, Monnereau C, Andraud C, Chaput F, Berthezène Y, Braun B, Jucker M, Åslund AK, Nyström S, Hammarström P, R Nilsson KP, Lindgren M, Wiart M, Chauveau F, and Parola S

Subjects
Mice, Rats, Animals, Tissue Distribution, Amyloid beta-Peptides metabolism, Mice, Transgenic, Brain diagnostic imaging, Brain metabolism, Multimodal Imaging, Disease Models, Animal, Alzheimer Disease diagnostic imaging, Nanoparticles
Abstract

Aim: To propose a new multimodal imaging agent targeting amyloid-β (Aβ) plaques in Alzheimer's disease. Materials & methods: A new generation of hybrid contrast agents, based on gadolinium fluoride nanoparticles grafted with a pentameric luminescent-conjugated polythiophene, was designed, extensively characterized and evaluated in animal models of Alzheimer's disease through MRI, two-photon microscopy and synchrotron x-ray phase-contrast imaging. Results & conclusion: Two different grafting densities of luminescent-conjugated polythiophene were achieved while preserving colloidal stability and fluorescent properties, and without affecting biodistribution. In vivo brain uptake was dependent on the blood-brain barrier status. Nevertheless, multimodal imaging showed successful Aβ targeting in both transgenic mice and Aβ fibril-injected rats.

Published
2022
Full Text
View/download PDF

39. Brain virtual histology with X-ray phase-contrast tomography Part I: whole-brain myelin mapping in white-matter injury models.

Author

Chourrout M, Rositi H, Ong E, Hubert V, Paccalet A, Foucault L, Autret A, Fayard B, Olivier C, Bolbos R, Peyrin F, Crola-da-Silva C, Meyronet D, Raineteau O, Elleaume H, Brun E, Chauveau F, and Wiart M

Abstract

White-matter injury leads to severe functional loss in many neurological diseases. Myelin staining on histological samples is the most common technique to investigate white-matter fibers. However, tissue processing and sectioning may affect the reliability of 3D volumetric assessments. The purpose of this study was to propose an approach that enables myelin fibers to be mapped in the whole rodent brain with microscopic resolution and without the need for strenuous staining. With this aim, we coupled in-line (propagation-based) X-ray phase-contrast tomography (XPCT) to ethanol-induced brain sample dehydration. We here provide the proof-of-concept that this approach enhances myelinated axons in rodent and human brain tissue. In addition, we demonstrated that white-matter injuries could be detected and quantified with this approach, using three animal models: ischemic stroke, premature birth and multiple sclerosis. Furthermore, in analogy to diffusion tensor imaging (DTI), we retrieved fiber directions and DTI-like diffusion metrics from our XPCT data to quantitatively characterize white-matter microstructure. Finally, we showed that this non-destructive approach was compatible with subsequent complementary brain sample analysis by conventional histology. In-line XPCT might thus become a novel gold-standard for investigating white-matter injury in the intact brain. This is Part I of a series of two articles reporting the value of in-line XPCT for virtual histology of the brain; Part II shows how in-line XPCT enables the whole-brain 3D morphometric analysis of amyloid- β (A β ) plaques., Competing Interests: The authors declare no conflicts of interest., (© 2022 Optical Society of America under the terms of the OSA Open Access Publishing Agreement.)

Published
2022
Full Text
View/download PDF

40. Matrix Metalloproteinase-9 Relationship With Infarct Growth and Hemorrhagic Transformation in the Era of Thrombectomy.

Author

Mechtouff L, Bochaton T, Paccalet A, Crola Da Silva C, Buisson M, Amaz C, Bouin M, Derex L, Ong E, Berthezene Y, Eker OF, Dufay N, Mewton N, Ovize M, Nighoghossian N, and Cho TH

Abstract

Objective: To assess the relationship between matrix metalloproteinase 9 (MMP-9), a proteolytic enzyme involved in the breakdown of the blood-brain barrier, and infarct growth and hemorrhagic transformation in acute ischemic stroke (AIS) with large vessel occlusion (LVO) in the era of mechanical thrombectomy (MT) using the kinetics of MMP-9 and sequential magnetic resonance imaging (MRI). Methods: HIBISCUS-STROKE is a cohort study including AIS patients with LVO treated with MT following admission MRI. Patients underwent sequential assessment of MMP-9, follow-up CT at day 1, and MRI at day 6. The CT scan at day 1 classified any hemorrhagic transformation according to the European Co-operative Acute Stroke Study-II (ECASS II) classification. Infarct growth was defined as the difference between final Fluid-Attenuated Inversion Recovery volume and baseline diffusion-weighted imaging volume. Conditional logistic regression analyses were adjusted for main confounding variables including reperfusion status. Results: One hundred and forty-eight patients represent the study population. A high MMP-9 level at 6 h from admission (H6) ( p = 0.02), a high glucose level ( p = 0.01), a high temperature ( p = 0.04), and lack of reperfusion ( p = 0.02) were associated with infarct growth. A high MMP-9 level at H6 ( p = 0.03), a high glucose level ( p = 0.03) and a long delay from symptom onset to groin puncture ( p = 0.01) were associated with hemorrhagic transformation. Conclusions: In this MT cohort study, MMP-9 level at H6 predicts infarct growth and hemorrhagic transformation., (Copyright © 2020 Mechtouff, Bochaton, Paccalet, Crola Da Silva, Buisson, Amaz, Bouin, Derex, Ong, Berthezene, Eker, Dufay, Mewton, Ovize, Nighoghossian and Cho.)

Published
2020
Full Text
View/download PDF

41. Clinical Imaging of Choroid Plexus in Health and in Brain Disorders: A Mini-Review.

Author

Hubert V, Chauveau F, Dumot C, Ong E, Berner LP, Canet-Soulas E, Ghersi-Egea JF, and Wiart M

Abstract

The choroid plexuses (ChPs) perform indispensable functions for the development, maintenance and functioning of the brain. Although they have gained considerable interest in the last years, their involvement in brain disorders is still largely unknown, notably because their deep location inside the brain hampers non-invasive investigations. Imaging tools have become instrumental to the diagnosis and pathophysiological study of neurological and neuropsychiatric diseases. This review summarizes the knowledge that has been gathered from the clinical imaging of ChPs in health and brain disorders not related to ChP pathologies. Results are discussed in the light of pre-clinical imaging studies. As seen in this review, to date, most clinical imaging studies of ChPs have used disease-free human subjects to demonstrate the value of different imaging biomarkers (ChP size, perfusion/permeability, glucose metabolism, inflammation), sometimes combined with the study of normal aging. Although very few studies have actually tested the value of ChP imaging biomarkers in patients with brain disorders, these pioneer studies identified ChP changes that are promising data for a better understanding and follow-up of diseases such as schizophrenia, epilepsy and Alzheimer's disease. Imaging of immune cell trafficking at the ChPs has remained limited to pre-clinical studies so far but has the potential to be translated in patients for example using MRI coupled with the injection of iron oxide nanoparticles. Future investigations should aim at confirming and extending these findings and at developing translational molecular imaging tools for bridging the gap between basic molecular and cellular neuroscience and clinical research.

Published
2019
Full Text
View/download PDF

42. Akinetic mutism reversibility after L-dopa therapy in unilateral left anterior cerebral artery infarction.

Author

Guery D, Ong E, and Nighoghossian N

Subjects
Dopamine Agents administration & dosage, Female, Humans, Infarction, Anterior Cerebral Artery diagnostic imaging, Levodopa administration & dosage, Magnetic Resonance Angiography, Magnetic Resonance Imaging, Middle Aged, Akinetic Mutism drug therapy, Akinetic Mutism etiology, Dopamine Agents pharmacology, Infarction, Anterior Cerebral Artery complications, Levodopa pharmacology
Published
2017
Full Text
View/download PDF

43. Cyclosporine in acute ischemic stroke.

Author

Nighoghossian N, Berthezène Y, Mechtouff L, Derex L, Cho TH, Ritzenthaler T, Rheims S, Chauveau F, Béjot Y, Jacquin A, Giroud M, Ricolfi F, Philippeau F, Lamy C, Turc G, Bodiguel E, Domigo V, Guiraud V, Mas JL, Oppenheim C, Amarenco P, Cakmak S, Sevin-Allouet M, Guillon B, Desal H, Hosseini H, Sibon I, Mahagne MH, Ong E, Mewton N, and Ovize M

Subjects
Aged, Aged, 80 and over, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Male, Middle Aged, Pilot Projects, Single-Blind Method, Brain Ischemia diagnosis, Brain Ischemia drug therapy, Cyclosporine administration & dosage, Stroke diagnosis, Stroke drug therapy, Thrombolytic Therapy trends
Abstract

Objectives: We examined whether IV administration of cyclosporine in combination with thrombolysis might reduce cerebral infarct size., Methods: Patients aged 18 to 85 years, presenting with an anterior-circulation stroke and eligible for thrombolytic therapy, were enrolled in this multicenter, single-blinded, controlled trial. Fifteen minutes after randomization, patients received either an IV bolus injection of 2.0 mg/kg cyclosporine (Sandimmune, Novartis) or placebo. The primary endpoint was infarct volume on MRI at 30 days. Secondary endpoints included infarct volume according to the site (proximal/distal) of arterial occlusion and recanalization after thrombolysis., Results: From October 2009 to July 2013, 127 patients were enrolled. The primary endpoint was assessed in 110 of 127 patients. The reduction of infarct volume in the cyclosporine compared with the control group was overall not significant (21.8 mL [interquartile range, IQR 5.1, 69.2 mL] vs 28.8 mL [IQR 7.7, 95.0 mL], respectively; p = 0.18). However, in patients with proximal occlusion and effective recanalization, infarct volume was significantly reduced in the cyclosporine compared with the control group (14.9 mL [IQR 1.3, 23.2 mL] vs 48.3 mL [IQR 34.5, 118.2 mL], respectively; p = 0.009)., Conclusions: Cyclosporine was generally not effective in reducing infarct size. However, a smaller infarct size was observed in patients with proximal cerebral artery occlusion and efficient recanalization., Classification of Evidence: This study provides Class I evidence that in patients with an acute anterior-circulation stroke, thrombolysis plus IV cyclosporine does not significantly decrease 30-day MRI infarct volume compared with thrombolysis alone., (© 2015 American Academy of Neurology.)

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results